Universal Biosensors, Inc. Board of Directors

Mr Andrew Denver BSc (Hons), MBA, FAICD
Non Executive Chairman



Between 2002 and 2005, Andrew was President of Pall Asia, a subsidiary of Pall Corporation, with responsibility for all Pall Corporation activities in the Asia Pacific region.

Andrew joined Pall in 2002 with the acquisition by Pall Corporation of US Filter’s Filtration and Separations business, where he was President. Andrew was appointed President and Chief Operating Officer of the US Filter Filtration and Separations Group in February 1998 after US Filter acquired Memtec Limited. Prior to his position at US Filter, Andrew was President and Chief Operating Officer of Memtec Limited from 1987 to 1997, and prior to that, at Baxter Healthcare Corporation where he was employed for 12 years in a number of positions. Andrew’s last assignment at Baxter Healthcare Corporation was as President of the corporation’s US based Medical Devices Division.

Andrew is a foundation member of The Principals Funds Management Pty Ltd, which helps Australian technology businesses commercialise their technologies. Andrew was a founding member and director of the Australian Environment Management Export Corporation and was the inaugural chairman for the first two years. Andrew was also a founding member and director of the Environment Management Industry Association of Australia. Andrew is a non executive director of CathRx Ltd, Anzon Australia Ltd and Cochlear Ltd.

Andrew graduated from the University of Manchester with a Bachelor of Science Degree (Honours) in Chemistry and achieved a distinction in his MBA at the Harvard Business School and is a Fellow of the Australian Institute of Company Directors. Andrew was appointed as a Director of Universal Biosensors on 31 December 2002.

Mr Mark Morrisson BSc (Hons)
Chief Executive Officer



Mark has extensive experience in the in vitro diagnostic and life science industries, a large part of which was spent as an executive, and more recently as a venture capital investor.

Mark trained as a biochemist at the University of Queensland in Australia before joining AGEN Biomedical Limited (‘AGEN’) in 1986, shortly before its public listing. AGEN was one of Australia’s first biotechnology start ups and was involved in the development of antibody based blood tests for a number of diseases. Shortly thereafter, Mark relocated to the east coast of the US where he was involved in product management for AGEN. In 1992, Mark was appointed Vice President of Marketing for North America and then subsequently as Vice President of Marketing for Europe, the Middle East and North Africa. In these positions, Mark served as a member of the new product committee and as a member of AGEN’s global management executive team. Other responsibilities in the role included new business development, development of strategic partnerships, licensing and contracts, and leading sales and marketing and distributor management efforts.

More recently, Mark has worked as an advisor and consultant for Thallo Biosciences, a San Francisco based corporate and strategic advisor serving the pharmaceutical, biotechnology and life sciences industries, and as Investment Manager for CM Capital Investments Pty Limited, a Brisbane based venture capital investor where he led that firm’s investment rounds into CathRx Ltd and Pharmaxis Ltd. Mark was previously a director of CathRx Ltd and an alternate director of Pharmaxis Ltd. Mark returned to Australia in July 2005 to take up his position with Universal Biosensors.

Mark holds a Bachelor of Science Degree in Biochemistry (Hons). Mark is the Chief Executive Officer of the Universal Biosensors Group and was appointed as a Director on 15 August 2006

Dr Colin Adam BE (Met), PhD
Non Executive Director



During 2000, Colin was the Acting Chief Executive of the Commonwealth Scientific and Industrial Research Organisation (‘CSIRO’). The CSIRO is the peak Australian Government body with a mission for technological development and industrial research and development. Prior to that, Colin was Deputy Chief Executive directly responsible for all the CSIRO’s commercial activity.

Colin’s career has included technology management positions within the US aerospace industry as Program Manager in advanced alloy development for Pratt & Whitney Aircraft in Florida and as Manager of the Materials Laboratory for Allied Corporation in New Jersey.

Colin subsequently became director of the Metals and Ceramics Laboratory, Corporate Technology for Allied. Colin has served as a member of the Commonwealth Government’s Industry Research and Development Board, the Australian Prime Minister’s Science Engineering and Innovation Council and the Victorian Premier’s Science, Engineering and Technology Taskforce. Colin serves on the board of Ausmelt Limited. Colin was previously a director of Memtec Limited, Melbourne IT Limited, and was Chairman of Tele IP Ltd and The Preston Group, an aviation software company sold to Boeing in 1999.

Colin has a Bachelor of Metallurgical Engineering Degree and a PhD in Metallurgy from the University of Queensland. Colin has been a director of Universal Biosensors Australia since 10 July 2002

Mr Denis Hanley AM, MBA, FCPA, FAICD
Non Executive Director



Denis Hanley is a qualified accountant and company director with more than 35 years experience in the management of technology-based growth businesses.

Denis spent 14 years with Baxter International Inc., a global medical products and services company. His career at Baxter included a number of international assignments including its Chicago headquarters, and his last position was Managing Director of Baxter’s Australian operations. In 1983, Denis was founding Chief Executive Officer and, in 1986, Executive Chairman of the Australian-based separations technology company, Memtec Limited. Under his leadership, Memtec grew into a global operating filtration and separations business with 1,700 employees, listed on the New York Stock Exchange. Since the sale of Memtec to US Filter in 1997, Denis has been a successful angel investor, assisting the commercialisation of several Australian technologies. Denis is non-Executive Chairman of Pharmaxis Ltd, CathRx Ltd and Lochard Ltd.

Denis holds an MBA with High Distinction from Harvard Graduate School of Business, where he was named a Baker Scholar. Denis was appointed as a Director on 21 September 2001.

Mr Andrew Jane BSc (Hons), MSc
Non Executive Director



Andrew joined CM Capital Investments Pty Ltd in 2003 as an Investment Manager and was promoted to Partner in 2006. Andrew began his career in academic research and the CSIRO and prior to becoming a venture capitalist, had a successful 10 year career in small entrepreneurial technology companies working in Australia, Japan and the US. Andrew is currently a director of Advent Pharmaceuticals Pty Limited and an observer to the board of Metastatix, Inc.

In 1994 Andrew was recruited to lead AGEN Biomedical Limited’s biosensor and instrumentation program which played a key role in the rapid expansion of AGEN’s export sales into the US. Andrew’s other major contribution at AGEN was to be the original internal start-up entrepreneur for the in vivo diagnostic imaging program for detecting blood clots, known as Thromboview, now in global Phase II trials.

In 1999 Andrew left AGEN and joined Lake Technology prior to its successful ASX listing later that year. As director of business development and licensing, Andrew worked closely with Lake Technology’s strategic partner, Dolby Laboratories in San Francisco, and was responsible for a significant number of global licensing deals during his four years there. The rapid growth of the company was recognised by Dolby, which acquired Lake Technology in 2004.

Andrew received his MSc in Instrumentation from the University of Manchester Institute of Science and Technology and holds a BSc (Honours) in Physics from St Andrews University in Scotland. Andrew was appointed as a Director on 15 August 2006

Mr Charles Kiefel BCom, FCA, FAICD
Non Executive Director



Charles is a Fellow of the Institute of Chartered Accountants in Australia and a Fellow of the Australian Institute of Company Directors. Charles has more than 20 years experience in finance, investment banking and the investment sector in London with Lazard Bros, New York with Lazard Freres, Sydney with Ord Minnett and Melbourne with ANZ Investment Bank. Charles has significant exposure on the buy-side of money management in a range of asset classes.

Charles is Chairman of the Military Superannuation Board, a substantial Australian pension fund and serves on the advisory boards of two of Australia’s largest private equity funds, Pacific Equity Partners Fund and CHAMP II Fund. Charles is a Director of Business Development for two major US money managers, Turner Investment Partners and LSV Asset Management. Charles is also a non executive director of Pharmaxis Ltd. Charles has been a director of Universal Biosensors Australia since 19 September 2002.

Dr Elizabeth (Jane) Wilson MBBS, MBA, FAICD
Non Executive Director



Jane is a professional company director with a background in medicine and finance. Jane has an MBA from the Harvard Business School where she studied agribusiness and the health sector. Jane is the current Chairman of IMBcom Limited (the commercialisation company of the Institute for Molecular Bioscience) and is Immediate Past President of the Australian Institute of Company Directors – Queensland Division, as well as a director of CathRx Ltd, UQ Holdings Ltd and the National Archives Advisory Council.

Jane is Finance Director of the Winston Churchill Memorial Trust and was the inaugural Chair of Horticulture Australia Ltd from 2000 to 2004. Jane is involved in a number of charitable and cultural organisations and has also served on the Queensland Government Biotechnology Taskforce, and the boards of Energex Ltd, WorkCover Queensland, AGEN Biomedical Limited and Protagonist Ltd. Jane is a member of the Queensland Premier’s Smart State Council and a member of the University of Queensland Senate.


Key Management

Dr Alastair Hodges BSc (Hons), PhD
Chief Scientist



Alastair has been working in the field of electrochemical sensors for the last 12 years. Alastair has a BSc (Hons) in chemistry and gained a PhD in electrochemistry from the University of Melbourne in 1987.
Alastair worked as a research scientist in the Defence Science and Technology Organisation and the CSIRO in the fields of electrochemistry and transport processes until 1995, when he joined Memtec Limited to work on sensor technologies. From 1999 to 2001 Alastair led a team that worked in the US on the development of glucose sensor technology.

Alastair has published thirteen papers in refereed journals, is the primary inventor of issued patents in 24 families and has pending patent applications in a further 10 families.

Mr Garry Chambers
Vice President of Operations



Garry started his career at the Royal Aircraft Establishment (UK) in research and development flight systems. In 1985, Garry transferred over to the medical field initially joining Chelsea Instruments (UK) and then subsequently joining MediSense (UK), one of the first biotechnology companies to produce mass market biosensors in 1986. Whilst at MediSense, Garry worked in research and development and was involved in a wide range of tasks from laboratory instrument design and manufacture to automated test equipment
for manufacturing.

In 1991, Garry migrated to Australia to join Memtec Limited to further his work on biosensor research and development. From 1999 to 2001, Garry was part of a core team based in the US, developing glucose sensors technology. Garry’s main focus was to establish a manufacturing system to complement the innovative sensor technology being developed. Garry is an inventor on 13 patents issued and pending.

Mr Salesh Balak BA, CA
Chief Financial Officer



Prior to joining the Universal Biosensors Group, Salesh was chief financial officer and company secretary of Pearl Healthcare Limited, a listed entity engaged in the manufacturing and healthcare sector. Salesh has also spent 13 years in the Business Services, Audit and Financial Advisory Services divisions of KPMG in both the Melbourne and Fiji offices.

Salesh holds a Bachelor of Arts in accounting and economics and is a member of the Institute of Chartered Accountants and Certified Practicing Accountants.

Mr. Cameron Billingsly LLB (Hons), BA
Company Secretary



Cameron has served as our Company Secretary since February 2006 and has been involved with Universal Biosensors as a corporate attorney since incorporation in 2001. Cameron is an accomplished corporate lawyer and is the principal and founder of PFM Legal Pty Ltd, a company established to provide company secretarial and general counsel services to Australian technology businesses. Cameron holds a Bachelor of Laws (Honours) and Bachelor of Arts from the University of Technology, Sydney.